• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule

    10/31/24 7:00:00 AM ET
    $CIA
    $EUDA
    $GOSS
    $LDTC
    Life Insurance
    Finance
    Medical/Nursing Services
    Health Care
    Get the next $CIA alert in real time by email

    MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces NRx Pharmaceuticals (NASDAQ:NRXP) will appear on the Emerging Growth Conference today in response to multiple requests and investor demand.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Jonathan Javitt, MD, MPH, Founder and Chairman will be discussing its first steps towards acquisition through its HOPE Therapeutics subsidiary of a national network of interventional psychiatry clinics focused on treatment of suicidal depression and PTSD with ketamine, transcranial magnetic stimulation, digital therapeutics, and other therapies that affect the NMDA receptor of the brain.

    NRx Pharmaceuticals will be presenting on October 31st from 11:25 to 11:55 eastern time.

    Register for the NRx Pharmaceuticals Conference here.

    Submit Questions for NRx Pharmaceuticals, Inc. to:

    [email protected]

    For updates, follow us on Twitter

    Updates to the Day 2 Schedule:

    10:30

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    10:45

    Introduction

    10:50 – 11:20

    Monumental Energy Corp. (OTCQB:MNMRF) (TSXV:MNRG)

    Keynote speaker: Maximilian Sali – VP Corporate Development Founder & Director

    11:25 – 11:55

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)

    Keynote speaker: Dr. Jonathan C. Javitt, Chairman and Interim CEO.

    12:00 - 12:30

    Vox Royalty Corp. (NASDAQ:VOXR) (TSX:VOXR)

    Keynote speakers: Kyle Floyd, Chairman & CEO & Chief Investment Officer

    12:35 – 1:05

    Stuhini Explorations, Ltd. (OTCQB:STXPF) (TSXV:STU)

    Keynote speaker: David O'Brien, President & CEO

    1:10 - 1:40

    Bioxytran, Inc. (OTCQB:BIXT)

    Keynote speakers: Mike Sheikh, Executive Vice President Business Development

    2:25 – 2:35

    Citizens, Inc. (NYSE:CIA)

    Keynote speakers: Jon Stenberg, President & CEO, and Jeff Conklin, CFO

    2:40 – 2:50

    Gossamer Bio, Inc. (NASDAQ:GOSS)

    Keynote speaker: Bryan Giraudo, CFO & COO

    2:55 – 3:05

    Interstellar Communication Holdings

    Keynote speakers: Seda Hewitt, Space Ambassador of IcMercury Harri Laitinen, Lifeguard of IcMercury, and Lijie Zhu, Capitan of icMercury

    3:10 - 3:20

    Sono Group N.V. (OTCQB:SEVCF)

    Keynote speaker: George O'Leary, Managing Director, CEO and CFO

    3:25 - 3:35

    Cyios Corp. (OTC:CYIO)

    Keynote speaker: John O'Shea, Chairman

    3:40 – 3:50

    NurExone Biologic Inc. (OTCQB:NRXBF) (TSXV:NRX)

    Keynote speaker: Dr. Lior Shaltiel, CEO

    3:55 – 4:05

    Evanesce

    Keynote speaker: Douglas Horne, Founder & CEO

    4:10 – 4:20

    LeddarTech Holdings, Inc. (NASDAQ:LDTC)

    Keynote speakers: Frantz Saintellemy – CEO & Chris Stewart, CFO

    4:25 – 4:35

    NCS Multistage Holdings, Inc. (NASDAQ:NCSM)

    Keynote speaker: Ryan Hummer, CEO & Director

    4:40 – 4:50

    EUDA Health Holdings Limited, (NASDAQ:EUDA)

    Keynote speaker: Kelvin Chen, CEO

    About NRx Pharmaceuticals, Inc.

    NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a healthcare delivery company developing the nation's first network of interventional psychiatry clinics targeting suicidal depression and PTSD through the use of ketamine, transcranial magnetic stimulation, digital therapeutics, and other therapies that target the brain's NMDA receptor. HOPE is committed to offering state of the art lifesaving therapy to the more than 3.4 million Americans who grapple with suicidal depression each year.

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the NRx Pharmaceuticals Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: [email protected]



    Primary Logo

    Get the next $CIA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • When and where will NRx Pharmaceuticals be presenting?

      NRx Pharmaceuticals (NASDAQ: NRXP) is set to present at the Emerging Growth Conference on October 31, 2024, at 11:25 AM to 11:55 AM Eastern Time.

    • Who will be the keynote speaker for NRx Pharmaceuticals at the conference, and what will be the focus of their presentation?

      Jonathan Javitt, MD, MPH, Founder and Chairman of NRx Pharmaceuticals, will discuss the company's acquisition strategies and the treatments being developed for suicidal depression and PTSD.

    • What is the purpose of the Emerging Growth Conference?

      The Emerging Growth Conference aims to connect small-cap companies with investors and highlights companies with strong management teams and innovative products.

    • What type of health conditions does NRx Pharmaceuticals aim to address with its therapeutics?

      NRx Pharmaceuticals focuses on treating central nervous system disorders, particularly suicidal bipolar depression, chronic pain, and PTSD, through its NMDA platform.

    • What is the role of HOPE Therapeutics in NRx Pharmaceuticals' strategy?

      HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, is planning to establish a national network of interventional psychiatry clinics specializing in advanced psychiatric treatments.

    Recent Analyst Ratings for
    $CIA
    $EUDA
    $GOSS
    $LDTC

    CompanyDatePrice TargetRatingAnalyst
    Gossamer Bio Inc.
    $GOSS
    7/14/2025$11.00Sector Outperform
    Scotiabank
    NRX Pharmaceuticals Inc.
    $NRXP
    4/2/2025$18.00Buy
    BTIG Research
    Gossamer Bio Inc.
    $GOSS
    6/25/2024$9.00Outperform
    Oppenheimer
    Gossamer Bio Inc.
    $GOSS
    4/5/2024$4.00Outperform
    Wedbush
    Gossamer Bio Inc.
    $GOSS
    7/27/2023$8.00 → $1.25Buy → Neutral
    UBS
    Gossamer Bio Inc.
    $GOSS
    3/7/2023Outperform → Mkt Perform
    Raymond James
    Gossamer Bio Inc.
    $GOSS
    3/1/2023Neutral
    Guggenheim
    Gossamer Bio Inc.
    $GOSS
    12/7/2022Neutral → Underweight
    JP Morgan
    More analyst ratings

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scotiabank initiated coverage on Gossamer Bio with a new price target

    Scotiabank initiated coverage of Gossamer Bio with a rating of Sector Outperform and set a new price target of $11.00

    7/14/25 8:51:47 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on NRx Pharmaceuticals with a new price target

    BTIG Research initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $18.00

    4/2/25 8:51:11 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Gossamer Bio with a new price target

    Oppenheimer initiated coverage of Gossamer Bio with a rating of Outperform and set a new price target of $9.00

    6/25/24 7:48:05 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CIA
    $EUDA
    $GOSS
    $LDTC
    SEC Filings

    View All

    NRX Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    8/18/25 4:31:21 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by NRX Pharmaceuticals Inc.

    424B5 - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    8/18/25 8:01:41 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by NRX Pharmaceuticals Inc.

    10-Q - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    8/18/25 6:07:13 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Leadership Updates

    Live Leadership Updates

    View All

    NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join Fireside Chat at BTIG Virtual Biotech Conference July 29 - 30, 2025

    WILMINGTON, Del., July 29, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", or the "Company"), today announced that its CEO and Chairman will join a fireside chat at BTIG Virtual Biotechnology Conference on July 29 – 30, 2025. Prof. Jonathan Javitt, MD, MPH will join Prof. Samuel Wilkinson, MD, of the Yale School of Medicine, and  BTIG Research Analyst Dr. Thomas Shrader for a fireside chat to discuss neuroplasticity in the treatment of CNS disorders at 8:00 a.m. EDT on Wednesday, July 30, 2025. Prof. Wilkinson is a widely published psychiat

    7/29/25 8:03:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics

    Kadima Neuropsychiatry Institute in La Jolla, CA expected to serve as clinical model for Hope treatment offerings nationwideKadima is a leading investigative site for CNS and psychedelic research, having served as the lead site in nearly all major trials in this spaceDr. David Feifel, a nationally recognized pioneer in interventional psychiatry to join HOPE as Chief Medical Innovation Officer upon closing Acquisition expected to be accretive to revenue and EBITDA for NRx and HOPEMIAMI, May 13, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ:NRXP), a clinic

    5/13/25 8:03:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LeddarTech Reports Annual Shareholder Meeting Results

    QUEBEC CITY, Canada, March 26, 2025 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc. ("LeddarTech" or the "Corporation") (NASDAQ:LDTC), an automotive software company that provides patented disruptive AI-powered low-level sensor fusion and perception software technology, LeddarVision™, announces the voting results of its annual general and special meeting of shareholders held on March 26, 2025 (the "Meeting"). Shareholders voted on various proposals and elected directors to the board. Key Highlights of the Meeting 1. Election of Directors: The full slate of six directors was elected to serve until the next annual meeting of shareholders or until a successor is elected or app

    3/26/25 8:18:50 PM ET
    $LDTC
    Computer Software: Prepackaged Software
    Technology

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream

    MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, August 20, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered

    8/20/25 7:00:00 AM ET
    $ADVM
    $CLNN
    $DERM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Diversified Commercial Services

    Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream

    MIAMI, Aug. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter. Day 1August 20, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the reg

    8/19/25 7:00:00 AM ET
    $ADVM
    $CLNN
    $DERM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Diversified Commercial Services

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medical need.Represents an approximately 10-fold expansion of the addressable market to 13 million Americans, compared to the original Fast Track Designation issued in 2017 for bipolar depression alone. The Designation letter contains a specific finding that NRX-100 addresses an "unmet medical need." This is a specific qualifying requirement for the Commissioner's National Priority Voucher Program.Filing of Commissioner's National Priority Voucher application for intravenous ketamine (NRX-100).Subm

    8/18/25 8:10:32 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider B Group, Inc. claimed ownership of 3,000,000 shares (SEC Form 3)

    3 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    8/21/25 6:21:37 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Milligan Sandra bought $50,016 worth of shares (26,050 units at $1.92), increasing direct ownership by 81% to 58,050 units (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    8/20/25 4:04:35 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operations Officer Lewis Bryon Matthew converted options into 2,625 units of Citizens and covered exercise/tax liability with 640 units of Citizens, increasing direct ownership by 16% to 14,680 units (SEC Form 4)

    4 - CITIZENS, INC. (0000024090) (Issuer)

    8/19/25 2:17:27 PM ET
    $CIA
    Life Insurance
    Finance

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Milligan Sandra bought $50,016 worth of shares (26,050 units at $1.92), increasing direct ownership by 81% to 58,050 units (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    8/20/25 4:04:35 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Stenberg Jon bought $66,407 worth of Citizens (19,914 units at $3.33), increasing direct ownership by 11% to 198,930 units (SEC Form 4)

    4 - CITIZENS, INC. (0000024090) (Issuer)

    6/18/25 2:42:21 PM ET
    $CIA
    Life Insurance
    Finance

    President & CEO Stenberg Jon bought $129,268 worth of Citizens (34,850 units at $3.71), increasing direct ownership by 20% to 179,016 units (SEC Form 4)

    4 - CITIZENS, INC. (0000024090) (Issuer)

    6/2/25 9:53:01 AM ET
    $CIA
    Life Insurance
    Finance

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Financials

    Live finance-specific insights

    View All

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medical need.Represents an approximately 10-fold expansion of the addressable market to 13 million Americans, compared to the original Fast Track Designation issued in 2017 for bipolar depression alone. The Designation letter contains a specific finding that NRX-100 addresses an "unmet medical need." This is a specific qualifying requirement for the Commissioner's National Priority Voucher Program.Filing of Commissioner's National Priority Voucher application for intravenous ketamine (NRX-100).Subm

    8/18/25 8:10:32 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

    Conference Call 8:00am ET, Wednesday August 20, 2025 WILMINGTON, Del., Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Tuesday, August 19, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.  The Company will host a conference call the following morning at 8:00am ET, Wednesday August 20, 2025. The Company requires addi

    8/13/25 6:06:00 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

    WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Thursday, August 14, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call at 4:30pm ET the same day. The call will provide a corporate and financial update, with a focus on recent regulatory events, regulatory strategy and go forward operational plans.   A live webcast of the conference call will be available on the Co

    8/11/25 4:05:00 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

    SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

    11/12/24 4:40:26 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

    SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

    11/12/24 9:55:14 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by LeddarTech Holdings Inc.

    SC 13D/A - LeddarTech Holdings Inc. (0001981462) (Subject)

    8/26/24 1:10:05 PM ET
    $LDTC
    Computer Software: Prepackaged Software
    Technology

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care